
Lysosomal storage diseases (LSDs) refer a group of genetic disorders that are caused by the deficiency of the lysosomal enzyme and activator proteins. Lysosomal enzyme helps in hydrolysis of protein, polysaccharide, DNA, RNA and lipid. In addition, lysosome also works as a waste disposal system of the cell by digesting unwanted material such as outside particles and unwanted macromolecules. Deficiency of lysosomal enzyme creates a defect in lysosomal functions, which results undigested material accumulation within the lysosome and causes disorders. Symptoms of lysosomal storage diseases are vary from person to person, it is depends on type of disorder, rate of progression, age of onset and others. Types of lysosomal diseases include gaucher disease, mucopolysaccharidosis, cystinosis, pompe disease and NPC. Some of the treatments for lysosomal storage diseases include enzyme replacement therapy, marrow replanting therapy and genetic therapy. On the basis of drug class global lysosomal storage diseases market can be segmented into ERTs, SRT and cystine-depletors.